Invesco’s Janux Therapeutics JANX Stock Holding History

Invesco’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$891K	Buy	58,002 +11,079	+24%	+$160K	﹤0.01%	2978
2026 Q1	$652K	Buy	46,923 +18,601	+66%	+$255K	﹤0.01%	3045
2025 Q4	$391K	Buy	28,322 +3,853	+16%	+$90.6K	﹤0.01%	3289
2025 Q3	$598K	Buy	24,469 +6,170	+34%	+$150K	﹤0.01%	3163
2025 Q2	$423K	Sell	18,299 -239,809	-93%	-$6.32M	﹤0.01%	3232
2025 Q1	$6.97M	Sell	258,108 -26,554	-9%	-$1M	﹤0.01%	1991
2024 Q4	$15.2M	Buy	284,662 +274,724	+2,764%	+$14.5M	﹤0.01%	1625
2024 Q3	$451K	Buy	9,938 +285	+3%	+$12.4K	﹤0.01%	3276
2024 Q2	$404K	Buy	9,653 +1,846	+24%	+$86.7K	﹤0.01%	3361
2024 Q1	$294K	Buy	+7,807	New	+$170K	﹤0.01%	3526

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Invesco's JANX Position: Q2 2026 in Review

Invesco increased its Janux Therapeutics (JANX) stake by 24% in Q2 2026, buying an estimated $160K and bringing the position to 58,002 shares worth $891K. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Invesco first reported a position in JANX in Q1 2024 and has held it in 10 quarters since. The position peaked at $15.2M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Invesco held 58,002 shares of Janux Therapeutics worth $891K as of Q2 2026.
Invesco bought 11,079 Janux Therapeutics shares in Q2 2026, an estimated $160K.
Janux Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2978 holding.
Invesco first reported a position in Janux Therapeutics in Q1 2024 and has held it in 10 quarters since.
Invesco's Janux Therapeutics position peaked at $15.2M in Q4 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.